

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 November 2007 (15.11.2007)

PCT

(10) International Publication Number  
**WO 2007/128987 A3**

(51) International Patent Classification:

**C07K 16/28** (2006.01) **A61P 35/00** (2006.01)  
**C07K 16/40** (2006.01) **G01N 33/573** (2006.01)  
**A61K 39/395** (2006.01) **C12N 9/54** (2006.01)  
**A61K 31/00** (2006.01)

(21) International Application Number:

PCT/GB2007/001312

(22) International Filing Date: 10 April 2007 (10.04.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0607158.3 10 April 2006 (10.04.2006) GB  
0620255.0 12 October 2006 (12.10.2006) GB

(71) Applicant (for all designated States except US): **FUSION ANTIBODIES LIMITED** [GB/GB]; P.O. Box 374, Belfast BT1 2WD (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **OLWILL, Shane** [GB/GB]; Fusion Antibodies Limited, PO Box 374, Belfast BT1 2WD (GB). **SCOTT, Christopher** [GB/GB]; Fusion Antibodies Limited, PO Box 374, Belfast BT1 2WD (GB). **GORMLEY, Julie** [GB/GB]; Fusion Antibodies Limited, PO Box 374, Belfast BT1 2WD (GB). **THOMAS, Jaquin** [GB/GB]; Fusion Antibodies Limited, PO Box 374, Belfast BT1 2WD (GB). **BURDEN, Roberta** [GB/GB]; Fusion Antibodies Limited, PO Box 374, Belfast BT1 2WD (GB). **MCMEEL, Darragh** [GB/GB]; Fusion Antibodies Limited, PO Box 374, Belfast BT1 2WD (GB). **JOHNSTON, James** [GB/GB]; Fusion Antibodies Limited, PO Box 374, Belfast BT1 2WD (GB).

(74) Agent: **MURGITROYD & COMPANY**; Scotland House, 165-169 Scotland Street, Glasgow G5 8PL (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(88) Date of publication of the international search report:  
10 January 2008

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THERAPY TARGETING CATHEPSIN S

(57) Abstract: The invention relates to a method of inhibiting chemotherapy induced upregulation of Cathepsin S on the surface of tumour cells, the method comprising the administration of a Cathepsin S inhibitor to said cells. Also provided is a therapy comprising an anti Cathepsin S antibody, in particular an anti-Cathepsin S antibody which does not inhibit the proteolytic effect of Cathepsin S but nevertheless inhibits angiogenesis and a combination treatment comprising a Cathepsin S inhibitor and a therapeutic agent.



WO 2007/128987 A3